These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 38771385)

  • 1. Moving towards a new era for the treatment of neuromyelitis optica spectrum disorders.
    Preziosa P; Amato MP; Battistini L; Capobianco M; Centonze D; Cocco E; Conte A; Gasperini C; Gastaldi M; Tortorella C; Filippi M
    J Neurol; 2024 Jul; 271(7):3879-3896. PubMed ID: 38771385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management.
    Kümpfel T; Giglhuber K; Aktas O; Ayzenberg I; Bellmann-Strobl J; Häußler V; Havla J; Hellwig K; Hümmert MW; Jarius S; Kleiter I; Klotz L; Krumbholz M; Paul F; Ringelstein M; Ruprecht K; Senel M; Stellmann JP; Bergh FT; Trebst C; Tumani H; Warnke C; Wildemann B; Berthele A;
    J Neurol; 2024 Jan; 271(1):141-176. PubMed ID: 37676297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging therapeutic targets for neuromyelitis optica spectrum disorder.
    Tradtrantip L; Asavapanumas N; Verkman AS
    Expert Opin Ther Targets; 2020 Mar; 24(3):219-229. PubMed ID: 32070155
    [No Abstract]   [Full Text] [Related]  

  • 4. Diagnosis and management of neuromyelitis optica spectrum disorders - An update.
    Bruscolini A; Sacchetti M; La Cava M; Gharbiya M; Ralli M; Lambiase A; De Virgilio A; Greco A
    Autoimmun Rev; 2018 Mar; 17(3):195-200. PubMed ID: 29339316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the complement system in neuromyelitis optica spectrum disorder.
    Asavapanumas N; Tradtrantip L; Verkman AS
    Expert Opin Biol Ther; 2021 Aug; 21(8):1073-1086. PubMed ID: 33513036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Satralizumab: A Review in Neuromyelitis Optica Spectrum Disorder.
    Fung S; Shirley M
    CNS Drugs; 2023 Apr; 37(4):363-370. PubMed ID: 36933107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Seropositive Neuromyelitis Optica in a Case of Undiagnosed Ankylosing Spondylitis: A Neuro-Rheumatological Conundrum.
    Ghosh Md R; Roy D; León-Ruiz M; Das S; Dubey S; Benito-León J
    Qatar Med J; 2022; 2022(3):29. PubMed ID: 35864917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies.
    Carnero Contentti E; Correale J
    J Neuroinflammation; 2021 Sep; 18(1):208. PubMed ID: 34530847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Memantine ameliorates motor impairments and pathologies in a mouse model of neuromyelitis optica spectrum disorders.
    Yick LW; Tang CH; Ma OK; Kwan JS; Chan KH
    J Neuroinflammation; 2020 Aug; 17(1):236. PubMed ID: 32782018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical characteristics of late-onset neuromyelitis optica spectrum disorder.
    Min W; Zhang L; Wang S; Xue M; Guo C; Zhu M
    Mult Scler Relat Disord; 2023 Feb; 70():104517. PubMed ID: 36708681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in the long-term treatment of neuromyelitis optica spectrum disorder.
    Anderson M; Levy M
    J Cent Nerv Syst Dis; 2024; 16():11795735241231094. PubMed ID: 38312734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Controversies in the management of neuromyelitis optica spectrum disorder.
    Bruscolini A; La Cava M; Mallone F; Marcelli M; Ralli M; Sagnelli P; Greco A; Lambiase A
    Expert Rev Neurother; 2019 Nov; 19(11):1127-1133. PubMed ID: 31339052
    [No Abstract]   [Full Text] [Related]  

  • 13. Neuromyelitis optica spectrum disorder: Pathogenesis, treatment, and experimental models.
    Wu Y; Zhong L; Geng J
    Mult Scler Relat Disord; 2019 Jan; 27():412-418. PubMed ID: 30530071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuromyelitis Optica (Devic's Syndrome): an Appraisal.
    Crout TM; Parks LP; Majithia V
    Curr Rheumatol Rep; 2016 Aug; 18(8):54. PubMed ID: 27402111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis.
    Jarius S; Aktas O; Ayzenberg I; Bellmann-Strobl J; Berthele A; Giglhuber K; Häußler V; Havla J; Hellwig K; Hümmert MW; Kleiter I; Klotz L; Krumbholz M; Kümpfel T; Paul F; Ringelstein M; Ruprecht K; Senel M; Stellmann JP; Bergh FT; Tumani H; Wildemann B; Trebst C;
    J Neurol; 2023 Jul; 270(7):3341-3368. PubMed ID: 37022481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuromyelitis optica spectrum disorder: pathophysiological approach.
    Mireles-Ramírez MA; Pacheco-Moises FP; González-Usigli HA; Sánchez-Rosales NA; Hernández-Preciado MR; Delgado-Lara DLC; Hernández-Cruz JJ; Ortiz GG
    Int J Neurosci; 2024 Aug; 134(8):826-838. PubMed ID: 36453541
    [No Abstract]   [Full Text] [Related]  

  • 17. The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders.
    Qin C; Chen B; Tao R; Chen M; Ma X; Shang K; Wu LJ; Wang W; Bu BT; Tian DS
    Mult Scler Relat Disord; 2019 Oct; 35():1-4. PubMed ID: 31276911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Neuromyelitis optica].
    Ferrán C; Pedemonte V; Turcatti E; González G
    Medicina (B Aires); 2019; 79 Suppl 3():60-65. PubMed ID: 31603846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein IgG associated disorder: A comprehensive neuro-ophthalmic review.
    Sharma J; Bhatti MT; Danesh-Meyer HV
    Clin Exp Ophthalmol; 2021 Mar; 49(2):186-202. PubMed ID: 33426799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aligning payer and provider strategies with the latest evidence to optimize clinical outcomes for patients with neuromyelitis optica spectrum disorder.
    Wingerchuk DM; Weinshenker BG; McCormick D; Barron S; Simone L; Jarzylo L
    J Manag Care Spec Pharm; 2022 Dec; 28(12-a Suppl):S3-S27. PubMed ID: 36427336
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.